Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T16:51:55.102Z.
Calculation as of: 2026-10-06T16:51:55.102Z.
Quote observation: 2026-10-06T16:49:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 521b0ab3da901f2a49dafbbedcb3688a082548b97bbb2cd5efdb729e6989e7c5
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
TuHURA Biosciences, Inc.
Market Cap
$121.95M
Price/FCF Ratio
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO |
|---|---|---|
| TuHURA Biosciences, Inc. (HURA) | $121.95M | N/A |
| Cibus, Inc. (CBUS)vs › | $122.13M | N/A |
| Spruce Biosciences, Inc. (SPRB)vs › | $122.48M | N/A |
| enGene Holdings Inc. (ENGN)vs › | $121.25M | N/A |
| Seer, Inc. (SEER)vs › | $121.11M | N/A |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $125.56M | N/A |
| Entera Bio Ltd. (ENTX)vs › | $126.10M | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $117.64M | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $116.75M | N/A |
| BGM Group Ltd. (BGM)vs › | $116.47M | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
